Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 1, 2012. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,000,000 Ordinary Shares of 25 pence each.
- Purchase Date: November 1, 2012.
- Price Range: Highest price paid was 1,394.5 pence per share; lowest price paid was 1,385.5 pence per share.
- Treasury Holdings (Settled): 517,290,427 shares (9.50% of total issued share capital).
- Treasury Holdings (Including Unsettled): 520,790,427 shares (10.57% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,928,103,862 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,000,000 shares for treasury. Consequently, the percentage of shares held in treasury increased to 9.50% of issued capital and 10.57% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (4,928,103,862) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated treasury share count (517,290,427 settled) for assessing dilution or buyback program progress.
- Note that the 10.57% voting rights figure includes shares purchased but not yet settled.